MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

42, respectively). In conclusion, glypican-1 IHC does not differentiate mesothelioma from pulmonary adenocarcinoma.
Comments Off on Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma.

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Rapamycin/crizotinib simultaneously inhibited mTORC1 (evidenced by S6 kinase and RPS6 dephosphorylation) and ALK signaling (ALK, AKT, STAT3 dephosphorylation), and crizotinib suppressed the adverse AKT activation induced by rapamycin. In conclusion, co-treatment with rapamycin and crizotinib is effective in suppressing MPM tumor growth and should be further explored as a therapeutic alternative in mesothelioma.
Comments Off on A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.

CONCLUSION: these results yielded to a diagnostic flowchart that we can use in routine practice and that is in accordance with the literature findings. Many diagnostic and technical pitfalls have to be known by pathologists when dealing with MPM.
Comments Off on How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

INTERPRETATION: The combination of tremelimumab and durvalumab appeared active, with a good safety profile in patients with mesothelioma, warranting further exploration. FUNDING: Network Italiano per la Bioterapia dei Tumori Foundation, Associazione Italiana per la Ricerca sul Cancro, AstraZeneca, and Istituto Toscano Tumori.
Comments Off on Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

In conclusion, disrupting Ang-Tie-2 signaling limits mesothelioma angiogenesis and halts tumor progression. Tumor vascularity, endothelial Tie-2 expression and tumor Ang-1 expression may predict mesothelioma response to Tek-deltaFc.
Comments Off on Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma

BAP1 loss was also absent in all pure WDPM cases but was identified in all WDPM with synchronous or metachronous MM. Similar genetic landscape in WDPM and MM components suggested their clonal relationship.
Comments Off on BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma

What is Mesothelioma?

Learn more about this fatal cancer, including the causes, symptoms, and treatments for both pleural and peritoneal tumors of the mesothelium at our parent site MesotheliomaCenter.

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

7 months, respectively. CONCLUSIONS: Combination cisplatin and gemcitabine HIOC can be administered safely and feasibly in the context of complete surgical resection of MPM by EPP or P/D.
Comments Off on A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma

Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Adoption of the modified RECIST 1. 1 guidelines for mesothelioma is recommended to harmonize the application of tumor measurement and response assessment across the next generation of clinical trials in this disease.
Comments Off on Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Comments Off on Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis

HVFs were more often in the Middle/South Atlantic regions, and less likely in New England, South, and Midwest. Notably, 75% of procedures at HVFs were P/Ds, versus 84% at LVFs (p .
Comments Off on Facility volume and postoperative outcomes for malignant pleural mesothelioma: A National Cancer Data Base analysis